Actively Recruiting
Improving Diagnosis and Understanding of Cephalosporin Allergy Through Double-Blind Skin Testing and Drug Challenges
Led by Massachusetts General Hospital · Updated on 2026-09-04
300
Participants Needed
6
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying cephalosporin allergy, a common cause of allergic reactions and anaphylaxis linked to beta-lactam antibiotics. Unlike penicillin allergy, cephalosporin allergy lacks clear diagnostic tests and understanding of its biological mechanisms. This trial aims to improve diagnosis, evaluate cross-reactivity among beta-lactam antibiotics, and explore the underlying causes to help develop better future tests. Participants undergo a series of double-blind skin tests and drug challenges with their suspected cephalosporin allergen and other related antibiotics. The trial includes randomized sequences of challenges to similar and dissimilar cephalosporins, followed by a penicillin challenge to assess cross-reactivity. These procedures are designed to provide empirical evidence on the best diagnostic approach and mechanisms involved. Throughout the study, participants attend up to four visits involving skin testing, blood sample collection, and carefully monitored drug challenges with observation periods. Those confirmed allergic receive additional challenges to assess cross-reactivity, while non-allergic participants complete the study earlier. Safety is closely monitored, and blood samples are collected at each visit to analyze immune responses. The entire participation lasts up to seven weeks, with long-term antibody studies extending to 54 months.
CONDITIONS
Brief Title
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Research Team
C
Cara Yelverton, BSc, PhD
K
Kell Lopez, BS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here